- In January 2025, Pepticom announced the successful closure of its Series A1 funding round, raising USD 6.6 million. The round was led by Japan Israel High Tech Ventures 2 LP, with strong support from existing investors. The funds will expedite the advancement of Pepticom's oral IL-17 inhibitor program, aimed at enhancing autoimmune diseases treatments. This includes the development of two families of fully synthetic, small cyclic peptidomimetic inhibitors with nanomolar activity, targeting both IL-17A and IL-17F isoforms.
- In January 2025, Bicycle Therapeutics plc announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated, cisplatin-ineligible patients with metastatic urothelial cancer (mUC). The company also highlighted recent achievements and outlined its strategic priorities and expected milestones for 2025.
- In November 2023, Chiesi Farmaceutici S.p.A and Haisco Pharmaceutical Group Co. Ltd. announced the signing of a Licensing Agreement to develop, manufacture, and commercialize HSK31858, a novel, reversible dipeptidyl peptidase 1 (DPP1) inhibitor for respiratory diseases, outside of greater China, including Hong Kong SAR, Macau SAR, and Taiwan District.
- In October 2023, UCB announced that the U.S. Food and Drug Administration (FDA) had approved ZILBRYSQ (zilucoplan) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive. Zilucoplan is the first once-daily subcutaneous (SC) peptide-based complement component 5 (C5) inhibitor and the only once-daily targeted therapy for gMG that allows self-administration in adults with anti-AChR antibody-positive gMG.
- In March 2023, Ono Pharmaceutical Co., Ltd. announced a drug discovery collaboration agreement with PeptiDream Inc. to discover and develop novel macrocyclic constrained peptide drugs targeting several of Ono’s areas of interest. As part of the agreement, PeptiDream will utilize its proprietary Peptide Discovery Platform System (PDPS) technology to identify and optimize macrocyclic constrained peptide drug candidates for multiple targets selected by Ono.
